76 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
7 May 24
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
4:02pm
for $160 Million Reimbursement Payment and Debt Repayment -
SAN DIEGO—(BUSINESS WIRE)— May 7, 2024 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage … .
◦Gossamer received a $160 million development reimbursement payment and is eligible to receive up to $146 million in regulatory and $180 million in sales
8-K
EX-99.1
GOSS
Gossamer Bio Inc
6 May 24
Entry into a Material Definitive Agreement
7:31am
& Other Indications
- Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory … will pay Gossamer $160 million as a development reimbursement. Additionally, Gossamer will be eligible to receive up to $146 million in regulatory milestones
8-K
GOSS
Gossamer Bio Inc
6 May 24
Entry into a Material Definitive Agreement
7:31am
and UK.
In consideration and as reimbursement for the Company’s development costs, Chiesi agreed to pay Gossamer $160 million. Additionally, Gossamer
8-K
EX-3.1
xw4 lwhsgkf17
27 Nov 23
Departure of Directors or Certain Officers
4:01pm
PRE 14A
0kbz2c
17 Apr 23
Preliminary proxy
4:01pm